Xenerex Biosciences, Inc.
Xenerex Biosciences, Inc., headquartered in the United States, is a pioneering entity in the biotechnology industry, specialising in innovative therapeutic solutions. Founded in the early 2000s, the company has achieved significant milestones, establishing itself as a leader in the development of advanced biopharmaceuticals aimed at addressing unmet medical needs. With a focus on neurology and rare diseases, Xenerex offers a unique portfolio of products that leverage cutting-edge research and technology. Their commitment to quality and efficacy sets them apart in a competitive market, positioning them as a trusted partner in healthcare. Notable achievements include successful clinical trials and collaborations with leading research institutions, underscoring their influence in the biosciences sector.
DitchCarbon Score
How does Xenerex Biosciences, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Xenerex Biosciences, Inc.'s score of 40 is lower than 100% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Xenerex Biosciences, Inc., headquartered in the US, currently does not have specific carbon emissions data available for the most recent year. As a current subsidiary of Otsuka Holdings Co., Ltd., Xenerex's climate commitments and initiatives are influenced by its parent company's sustainability strategies. While no direct emissions data is reported, Xenerex benefits from the climate initiatives and targets set by Otsuka Holdings, which operates at a cascade level of 4. This includes commitments to the Science Based Targets initiative (SBTi) and participation in the Carbon Disclosure Project (CDP). These initiatives aim to reduce greenhouse gas emissions across various scopes, although specific reduction targets for Xenerex have not been detailed. Xenerex is aligned with Otsuka Pharmaceutical Co., Ltd.'s SBTi targets, which are established at a cascade level of 3, indicating a structured approach to climate action within the corporate family. The company is also part of the RE100 initiative, committing to 100% renewable energy, and is influenced by broader sustainability goals set by Otsuka Holdings. In summary, while Xenerex Biosciences, Inc. does not currently report specific emissions data or reduction targets, it is integrated into a robust framework of climate commitments through its parent company, Otsuka Holdings, which actively pursues sustainability and emissions reduction initiatives.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
| 2011 | 2012 | 2016 | 2017 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|---|---|---|
| Scope 1 | 285,728,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
| Scope 2 | 116,816,000 | 000,000,000 | 000,000,000 | - | 00,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
| Scope 3 | 402,544,000 | 000,000,000 | 000,000,000 | - | 000,000,000 | 000,000,000 | 000,000,000 | 000,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Xenerex Biosciences, Inc. is not participating in any of the initiatives that we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
